Original Investigation
Impact of Achieved Blood Pressures on Mortality Risk and End-Stage Renal Disease Among a Large, Diverse Hypertension Population

https://doi.org/10.1016/j.jacc.2014.04.065Get rights and content
Under an Elsevier user license
open archive

Abstract

Background

Medical data or clinical guidelines have not adequately addressed the ideal blood pressure (BP) treatment targets for survival and renal outcome.

Objectives

This study sought to evaluate ranges of treated BP in a large hypertension population and compare risk of mortality and end-stage renal disease (ESRD).

Methods

A retrospective cohort study within the Kaiser Permanente Southern California health system was performed from January 1, 2006, to December 31, 2010. Treated hypertensive subjects ≥18 years of age were studied. Cox proportional hazards regression models were used to evaluate the risks (hazard ratios) for mortality and/or ESRD among different BP categories with and without stratification for diabetes mellitus and older age.

Results

Among 398,419 treated hypertensive subjects (30% with diabetes mellitus), mortality occurred in 25,182 (6.3%) and ESRD in 4,957 (1.2%). Adjusted hazard ratios (95% confidence intervals [CI]) for composite mortality/ESRD in systolic BP <110, 110 to 119, 120 to 129, 140 to 149, 150 to 159, 160 to 169, and ≥170 compared with 130 to 139 mm Hg were 4.1 (95% CI: 3.8 to 1.3), 1.8 (95% CI: 1.7 to 1.9), 1.1 (95% CI: 1.1 to 1.1), 1.4 (95% CI: 1.4 to 1.5), 2.3 (95% CI: 2.2 to 2.5), 3.3 (95% CI: 3.0 to 3.6), and 4.9 (95% CI: 4.4 to 5.5) respectively. Diastolic BP 60 to 79 mm Hg were associated with the lowest risk. The nadir systolic and diastolic BP for the lowest risk was 137 and 71 mm Hg, respectively. Stratified analyses revealed that the diabetes mellitus population had a similar hazard ratio curve but a lower nadir at 131 and 69 mm Hg but age ≥70 had a higher nadir (140 and 70 mm Hg).

Conclusions

Both higher and lower treated BP compared with 130 to 139 mm Hg systolic and 60 to 79 mm Hg diastolic ranges had worsened outcomes. Our study adds to the growing uncertainty about BP treatment targets.

Key Words

blood pressure goals
hypertension treatment
mortality risk
renal failure risk
treatment risk

Abbreviations and Acronyms

BMI
body mass index
BP
blood pressure
CCI
Charlson comorbidity index
CI
confidence interval
CKD
chronic kidney disease
DBP
diastolic blood pressure
DM
diabetes mellitus
eGFR
estimated glomerular filtration rate
ESRD
end-stage renal disease
HR
hazards ratio
HTN
hypertension
ICD-9
International Classifications of Diseases-Ninth Revision
KPSC
Kaiser Permanente Southern California
SBP
systolic blood pressure

Cited by (0)

This study was supported by Kaiser Permanente Southern California Regional Research and by a research grant #R01 DK078106 from the National Institute of Diabetes, Digestive and Kidney Disease (to Drs. Kovesdy, Kalantar-Zadeh, and Jacobsen). Additional support was also provided by the National Institutes of Health grants #K24-DK091419 (to Dr. Kalantar-Zadeh) and #R01-DK096920 (to Drs. Kovesdy and Kalantar-Zadeh). Dr. Sim has received research grants from Questcor Pharmaceuticals, Sanofi Aventis, and Keryx Pharmaceuticals. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Listen to this manuscript's audio summary by JACC Editor-in-Chief Dr. Valentin Fuster.

You can also listen to this issue's audio summary by JACC Editor-in-Chief Dr. Valentin Fuster.